Vasospasm induced myocardial ischaemia secondary to sumatriptan use
Authors:
- 24 August 2020
- journal article
- research article
- Published by BMJ in BMJ Case Reports
- Vol. 13 (8) , e235387
Abstract
Certain medications have been implicated in causing acute myocardial infarctions (AMI). Sumatriptan, a medication usually prescribed for acute migraine and cluster headaches has been documented as potentially causing coronary vasospasm, thereby leading to MI. This is usually seen in patients with strong risk factors for coronary artery disease (CAD) or in those with established CAD. Most cases thus far have been reported in patients using the subcutaneous preparation of sumatriptan. Here, we present a case of a patient without prior risk factors for CAD and angiographically unremarkable coronary arteries who presented with evidence of an AMI after oral sumatriptan use for migraines.Keywords
This publication has 18 references indexed in Scilit:
- New Light on a Forgotten DiseaseJACC, 2011
- Sumatriptan therapy for headache and acute myocardial infarctionExpert Opinion on Pharmacotherapy, 2010
- Triptans and troponin: a case reportOrphanet Journal of Rare Diseases, 2009
- Current clinical features, diagnostic assessment and prognostic determinants of patients with variant anginaInternational Journal of Cardiology, 2007
- Tolerability of sumatriptan: clinical trials and post-marketing experienceCephalalgia, 2000
- Fatal Cardiac Arrhythmia After Oral SumatriptanHeadache: The Journal of Head and Face Pain, 1999
- Vasospasm‐lnduced Myocardial Infarction With SumatriptanHeadache: The Journal of Head and Face Pain, 1996
- Unstable angina pectoris associated with imitrex therapyCatheterization and Cardiovascular Diagnosis, 1995
- Treatment of Migraine Attacks with SumatriptanNew England Journal of Medicine, 1991
- 5-hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activationEuropean Journal of Pharmacology, 1989